Streetbeat News

Products Services

VEEE

Twin Vee PowerCats Co. (NASDAQ:VEEE) is developing a new 'Pro-Direct Platform' to revolutionize the boat buying experience, inspired by the automotive industry. This initiative aims to enhance customer satisfaction and expand market reach.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:30 pm

BOSC

BOS Better Online Solutions Ltd. (NASDAQ:BOSC) has received a $900,000 order from an Israeli aerospace customer, to be delivered through 2024. This highlights BOSC's reliability and quality in supply chain services.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:29 pm

BIVI

BioVie has received approval from the U.S. Army Medical Research and Development Command to evaluate its drug Bezisterim for Long Covid. The company also secured $13.1 million in funding.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:27 pm

URGN

UroGen Pharma Ltd. has received a Notice of Allowance from the USPTO for a new patent covering its RTGel® technology combined with medac's mitomycin formulation. This patent, once issued, will protect UroGen's UGN-103 and UGN-104 programs until December 2041, targeting specific urothelial cancers.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:26 pm

KRRO

Korro Bio's stock is rising following a collaboration announcement with Novo Nordisk to develop genetic medicines targeting cardiometabolic diseases.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:26 pm

CCM

Concord Medical Services Holdings Limited (NYSE:CCM) announced that its subsidiary, Guangzhou Concord Cancer Center, has obtained a large medical equipment procurement license for its proton therapy equipment. This approval allows the hospital to offer proton therapy treatment services.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:25 pm

TOVX

Theriva Biologics (NYSE:TOVX) has been awarded €2.28 million from the Spanish government's National Knowledge Transfer Program to support a collaboration with Universitat Autònoma de Barcelona. The funding will advance Theriva's suspension cell platform for manufacturing virus therapies.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:24 pm

TIL

Instill Bio shares are trading lower following the announcement of their global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in combination with chemotherapy for treating front-line non-small cell lung cancer and triple-negative breast cancer.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:22 pm

BCAB

BioAtla presented promising Phase 2 trial data for ozuriftamab vedotin, showing a 32% overall response rate in heavily pretreated patients with squamous cell carcinoma of the head and neck. The treatment was well tolerated, and BioAtla plans to discuss a potential registrational trial with the FDA in 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:22 pm

INNV

InnovAge Holding Corp. (NASDAQ:INNV) has been selected as a research partner for a national study on preventing falls among seniors. This aligns with National PACE Awareness Month and Falls Prevention Month, highlighting InnovAge's role in reducing falls through proactive measures.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:21 pm